Clinical trial
Study for Treatment of Moderate or Severe, Periodic, "Cyclic", Breast Pain
NCT00237523 · Symbollon Pharmaceuticals, Industry · Unknown status
Key facts
| NCT number | NCT00237523 |
|---|---|
| Title | Study for Treatment of Moderate or Severe, Periodic, "Cyclic", Breast Pain |
| Official title | A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of IoGen™ for the Treatment of Moderate or Severe, Periodic Breast Pain Associated With Symptomatic Fibrocystic Breast Disease |
| Lead sponsor | Symbollon Pharmaceuticals, Industry |
| Status | Unknown status |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Fibrocystic Disease of Breast, Fibrocystic Changes of Breast, Fibrocystic Mastopathy, Pain |
| Intervention type | Drug |
| Interventions | IoGen (molecular iodine) |
| Enrollment | 175 |
| Start date | Jul 1, 2005 |
| Completion | Mar 1, 2008 |
| First posted | Oct 12, 2005 |
| Last update posted | Jun 18, 2007 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: